Combination Chemotherapy With Doxorubicin and Lomustine: Treatment of Refractory Hodgkin's Disease

Stephen D. Williams, Lawrence H. Einhorn

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Ten patients with advanced Hodgkin's disease refractory to combination therapy with nitrogen mustard, vincristine sulfate, procarbazine, and prednisone (MOPP) were treated with a combination of doxorubicin hydrochloride and lomustine. Toxicity was acceptable. Five patients (50%) attained complete remission (median duration, 15 months). Three patients attained a partial remission (median duration, four months). Survival ranged from three to more than 40 months, and five patients are still alive. One patient remains disease-free after a course of radiation therapy to a site of localized nodal relapse. The doxorubicin-lomustine regimen has induced meaningful remissions in a patient population with very refractory disease.

Original languageEnglish (US)
Pages (from-to)1659-1661
Number of pages3
JournalJAMA: The Journal of the American Medical Association
Volume238
Issue number15
DOIs
StatePublished - Oct 10 1977

Fingerprint

Lomustine
Combination Drug Therapy
Hodgkin Disease
Doxorubicin
Therapeutics
Procarbazine
Mechlorethamine
Vincristine
Prednisone
Radiotherapy
Recurrence
Survival
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Combination Chemotherapy With Doxorubicin and Lomustine : Treatment of Refractory Hodgkin's Disease. / Williams, Stephen D.; Einhorn, Lawrence H.

In: JAMA: The Journal of the American Medical Association, Vol. 238, No. 15, 10.10.1977, p. 1659-1661.

Research output: Contribution to journalArticle

@article{8e88edcb1bcb445a92cad996af0f5704,
title = "Combination Chemotherapy With Doxorubicin and Lomustine: Treatment of Refractory Hodgkin's Disease",
abstract = "Ten patients with advanced Hodgkin's disease refractory to combination therapy with nitrogen mustard, vincristine sulfate, procarbazine, and prednisone (MOPP) were treated with a combination of doxorubicin hydrochloride and lomustine. Toxicity was acceptable. Five patients (50{\%}) attained complete remission (median duration, 15 months). Three patients attained a partial remission (median duration, four months). Survival ranged from three to more than 40 months, and five patients are still alive. One patient remains disease-free after a course of radiation therapy to a site of localized nodal relapse. The doxorubicin-lomustine regimen has induced meaningful remissions in a patient population with very refractory disease.",
author = "Williams, {Stephen D.} and Einhorn, {Lawrence H.}",
year = "1977",
month = "10",
day = "10",
doi = "10.1001/jama.1977.03280160053028",
language = "English (US)",
volume = "238",
pages = "1659--1661",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "15",

}

TY - JOUR

T1 - Combination Chemotherapy With Doxorubicin and Lomustine

T2 - Treatment of Refractory Hodgkin's Disease

AU - Williams, Stephen D.

AU - Einhorn, Lawrence H.

PY - 1977/10/10

Y1 - 1977/10/10

N2 - Ten patients with advanced Hodgkin's disease refractory to combination therapy with nitrogen mustard, vincristine sulfate, procarbazine, and prednisone (MOPP) were treated with a combination of doxorubicin hydrochloride and lomustine. Toxicity was acceptable. Five patients (50%) attained complete remission (median duration, 15 months). Three patients attained a partial remission (median duration, four months). Survival ranged from three to more than 40 months, and five patients are still alive. One patient remains disease-free after a course of radiation therapy to a site of localized nodal relapse. The doxorubicin-lomustine regimen has induced meaningful remissions in a patient population with very refractory disease.

AB - Ten patients with advanced Hodgkin's disease refractory to combination therapy with nitrogen mustard, vincristine sulfate, procarbazine, and prednisone (MOPP) were treated with a combination of doxorubicin hydrochloride and lomustine. Toxicity was acceptable. Five patients (50%) attained complete remission (median duration, 15 months). Three patients attained a partial remission (median duration, four months). Survival ranged from three to more than 40 months, and five patients are still alive. One patient remains disease-free after a course of radiation therapy to a site of localized nodal relapse. The doxorubicin-lomustine regimen has induced meaningful remissions in a patient population with very refractory disease.

UR - http://www.scopus.com/inward/record.url?scp=0017751347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017751347&partnerID=8YFLogxK

U2 - 10.1001/jama.1977.03280160053028

DO - 10.1001/jama.1977.03280160053028

M3 - Article

C2 - 578254

AN - SCOPUS:0017751347

VL - 238

SP - 1659

EP - 1661

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 15

ER -